Parameter
| Biomarker | KRAS mutations | Full name | Kirsten rat sarcoma viral oncogene homolog mutations | Molecular Type | Genetic mutations |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Treatment prediction and prognosis | ||
| Disease | Colorectal Cancer (CRC) | Disease Subtypes | / | ||
| Organ | Colorectal | Test Sample / Technology Platform | Tumor tissue/blood (NGS, PCR) | ||
| Pathobiological Mechanisms | Activating mutation of KRAS gene leads to the continuous activation of PI3K/AKT pathway, which promotes tumor proliferation and chemotherapy resistance | ||||
| Clinical Availability Status | Clinical treatment options (available) : has been included in CRC guidelines, as an EGFR treatment rule out marker | ||||
| Notes and Dynamics | It is one of the most common driver mutations in CRC. Liquid biopsy can monitor its dynamic changes in real time and guide the adjustment of treatment plan | ||||